Loading clinical trials...
Loading clinical trials...
A Post-marketing Clinical Study of the Inactivated SARS-CoV-2 Vaccine (Vero Cells) (Produced in Wuhan): Immunogenicity and Safety Assessments in Patients With Hypertension and/or Diabetes
Conditions
Interventions
COVAX
Locations
3
China
Nan'an Center for Disease Control and Prevention
Quanzhou, Fujian, China
Songtao Miao Autonomous County Center for Disease Control and Prevention
Tongren, Guizhou, China
You County Center for Disease Control and Prevention
Zhuzhou, Hunan, China
Start Date
October 1, 2021
Primary Completion Date
January 1, 2022
Completion Date
March 1, 2022
Last Updated
October 25, 2021
NCT06927622
NCT05531032
NCT04466098
NCT04930874
NCT05077917
NCT04821934
Lead Sponsor
China National Biotec Group Company Limited
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions